Keysight is the photonics test stock to buy now because the 1.6T production ramp, where the big checks get cashed, has not yet peaked and Keysight is the least exposed to a major correction. It reported $1.6B in revenue with 30% year-over-year growth projected for Q2, and is buying back $1.5B of stock because it sees the 1.6T cycle lasting through 2028. Its diversified $57B market cap makes it safer than Aehr, which has run too far too fast; Goldman has a $384 target. x.com